Nxera Pharma

4565.TPharmaceutical

Filed as Sosei Group Corporation (2022-08–2024-03)

Key numbers · FY ended 2025-12

Revenue¥29.6bn+2.7% YoY Operating income−¥8.5bn—Net income (owners)−¥12.5bn—Total assets¥134.8bn-11.0% YoY EPS (basic)¥-138.8-157.4% YoY

Full financial history and reports →

Stock price4565 · View chart ↗

Open the price chart on TradingView.

Latest filings

Thu, Apr 30 · JST1 filing

09:005% STAKENxera Pharma · Gomi Daisuke · 10.64% → 11.67%+1.03pp

Fri, Dec 12 · JST1 filing

16:37MATERIALNxera Pharma · Change in major shareholder

Fri, Dec 5 · JST1 filing

16:18MATERIALNxera Pharma · Event with a material impact on financial position

Thu, Dec 4 · JST1 filing

16:485% STAKENxera Pharma · Gomi Daisuke · 9.50% → 10.64%+1.14pp

Wed, Jun 25 · JST1 filing

16:355% STAKENxera Pharma · Taiyo Pacific Partners L.P. · 5.86% → 4.80%−1.06pp

All filings →

Major holders (5%+) · 1

Holder	Stake	Change	Filed
Gomi Daisuke	11.67%	+1.03pp	2026-04-30

Each holder's own ratio from its most recent large-shareholding report.